Abington, Pennsylvania Clinical Trials

A listing of Abington, Pennsylvania clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 49 clinical trials
A Study Evaluating The Safety Tolerability Pharmacokinetics And Efficacy Of Venetoclax In Combination With Atezolizumab Carboplatin And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.

cancer therapy
maintenance therapy
cancer
chemoradiotherapy
measurable disease
Fox Chase Cancer Center
 (4.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +15 other locations
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

analgesics
antiandrogen therapy
cancer
prednisone
orchiectomy
Research Site
 (4.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +106 other locations
A Study Evaluating The Safety Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: [1] Part A: Safety run-in cohort of approximately 12 participants; [2] Part B: Expansion cohort …

cancer
docetaxel
adenocarcinoma of prostate
hair thinning
progression of prostate cancer
Fox Chase Cancer Center
 (4.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +17 other locations
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.

mental state examination
alzheimer's disease
apolipoprotein e4
mini-mental state examination
Accepts healthy volunteers
Abington Neurological Associates
 (1.9 away) Contact site
  • 32 views
  • 20 Sep, 2024
  • +126 other locations
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

platelet count
17p deletion
absolute neutrophil count
blood transfusion
bone marrow procedure
Consultants in Medical Oncology and Hematology, P.C.
 (4.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +50 other locations
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection. In addition to SOC, the brequinar group will receive 5 daily doses of brequinar 100 mg.

coronavirus infection
dyspnea
cough
fever
pao2
Temple University
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations
UPENN Case Test Trial 13 (Do Not Make Any Changes)

UPENN Case Test Trial 13 (Do Not Make Any Changes)

Abington Neurological Associates- Site Number : 8401065
 (1.3 away) Contact site
  • 0 views
  • 15 May, 2025
  • 1 location
Phase I Study in Advanced Malignancies

RDT aims to take advantage of the relatively safer toxicity profiles of both lower dose radiation therapy and systemic ALA to treat non-superficial lesions in a manner similar to photodynamic therapy. The doses of radiation administered in this study will be lower than those typically used to treat cancer. However, …

cancer
absolute neutrophil count
hair thinning
mitomycin
serum total bilirubin level
Fox Chase Cancer Center
 (4.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients.

SARS
cancer
nasal swab
oximetry
acute respiratory syndrome (sars)
Temple University Hospital
 (7.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Clinician Communication About Sexual Health

The objective of this study is to adapt a previously tested brief intervention aimed at enhancing clinicians communication about sexual health (iSHARE) to a mobile web-based platform showcasing a two-part podcast and to assess the feasibility, acceptability, and preliminary effects of the intervention in breast cancer clinicians.

Fox Chase Cancer Center
 (4.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location